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A two-stage procedure for estimating sensitivity and specificity is described. The procedure is developed in the context of a validation study for self-
reported atypical nevi, a potentially useful measure in the study of risk factors for malignant melanoma. The first stage consists of a sample of N
individuals classified only by the test measure. The second stage is a subsample of size m, stratified according the information collected in the first
stage, in which the presence of atypical nevi is determined by clinical examination. Using missing data methods for contingency tables, maximum
likelihood estimators for the joint distribution of the test measure and the "gold standard" clinical evaluation are presented, along with efficient
estimators for the sensitivity and specificity. Asymptotic coefficients of variation are computed to compare alternative sampling strategies for the second
stage. - Environ Health Perspect 102(Suppl 8):11-14(1994)
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Introduction
In epidemiologic research, validation studies
often have as a goal the determination of
the sensitivity and specificity of a "test" for
the presence of a risk factor. This test is
usually easier and cheaper to administer
than a more accurate "gold standard"
method. Knowledge of the specificity and
sensitivity ofthe test can be used in sample
size calculations for subsequent studies of
the effect of the risk factor and to adjust
relative risk estimates for measurement
error. This knowledge can also be impor-
tant in the evaluation of the clinical utility
ofthe test as a diagnostic tool.
An example ofthe use of a test measure
occurs in epidemiologic studies of inci-
dence and prevalence ofneoplastic skin dis-
ease, where the use ofself-reported counts
ofatypical nevi rather than clinical exami-
nation can lead to substantial reduction in
study costs. Recent studies of the impor-
tance ofthe presence ofnevi as a predictor
of melanoma have employed both self-
reported counts [e.g., Bain et al. (1)] and
physical examination by a dermatologist or
trained interviewer [e.g., Augustsson et al.
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(2,3)]. However, the sensitivity and speci-
ficity ofself-reports ofthe presence ofatyp-
ical nevi are not well known, although
validation studies ofself-reported aggregate
measures ofbody nevus density (4) suggest
a measurable correlation with interviewer
determinations, and studies using both
types of data are able to show significant
relative risks for melanoma using either
measure (5).
A recent survey in Sweden sucessfully
solicited mail questionnaire responses from
50,000 women between the ages of35 and
55 ("Women's Lifestyles and Health
Study," H-O Adami, unpublished).
Respondents were asked to examine their
skin for the presence ofatypical moles. At
present, no analysis of the results of the
survey has been performed. A number of
alternative designs are being considered to
use the survey to estimate the sensitivity
and specificity ofself-reported atypical nevi
(SRAN). Specifically, a two-stage proce-
dure is proposed in which the first stage
would be a random sample of the original
cohort to determine the prevalence of
SRAN. In the second stage, a random sam-
ple ofthe individuals identified in the first
stage would be examined to obtain
physician-diagnosed atypical nevi (PDAN).
The second-stage sample could be stratified
by level ofSRAN as determined in the first
stage. In this case, an advantage in estimating
sensitivity and specificity could be achieved
by manipulating the relative sizes of the
test positive and test negative samples.
The purpose ofthis article is to demon-
strate the utility of a two-stage validation
study design as applied to self-reported
counts ofatypical nevi. In the sections that
follow, estimators for sensitivity and speci-
ficity in the proposed designs are described,
along with their approximate standard
errors. The relative efficiencies of the
designs are used to compare the proposed
designs and to assess the design for the
SRAN validation study.
Design Options
Figure 1 depicts two possible designs for a
validation study. Under design A, a first-
stage, simple random sample of size Nis
take to obtain SRAN. Then a second-stage
subsample of size m is taken to obtain
PDAN. As a result, the validation study
contains m complete observations.
A
B N
Figure 1. Design options for two-stage study. (A)
Select Nto get SRAN and random subsample mto get
PDAN. (B) Select Nto get SRAN. Take random sample
of size mo from negative SRAN and ml from positive
SRAN.
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At the first stage, design B also specifies a
sample ofsize Nto obtain SRAN. How-
ever, in the second stage the number of
individuals selected who have a positive
SRAN, ml, and the number ofindividuals
who have a negative SRAN, mO are con-
trolled, under the constraint that mo+ml= m.
For simplicity, it is assumed that the
counts ofatypical nevi have been reduced
to a binary classification (i.e., presence or
absence of nevi). The object ofthe design
is to manipulate the ratio mI/mo to achieve
a higher precision than the other designs at
an equivalent cost. Ofcourse, it is not pos-
sible for ml to exceed the number of test
positives in the first stage, NI, or for mo to
exceed the number of test negatives in the
first stage, No.
The data from both these designs can
be arranged as in Figure 2. The number of
complete observations is m, the size of the
second stage in both designs A and B. The
number of incomplete observations is
r = N- m. These are the individuals not
selected for the second stage, and thus only
having the SRAN (test) classification. In
design A, the margins ml and mo are not
fixed, whereas in design B, they are chosen
to achieve design objectives such as mini-
mizing the variance of estimators of sensi-
tivity and specificity.
Estimation
In describing the methods of estimation
and the properties of the estimators, the
following notation will be adopted. Let {in,
i = 0,1;j= 0,1} represent the joint distribu-
tion of the binary indicators SRAN and
PDAN, with i indexing the level of SRAN
andj indexing the level of PDAN. Thus
s1O is the probability that SRAN is one or
more and PDAN is zero. Sensitivity can be
expressed as s = nil/(no, + 11), and speci-
ficity as S= 'oo/(ntoo+io). The prevalence
is Xt = it(1I +i11. To simplify the following
developments, let 9 = (0oo,IolI rlo, 11)t)
The primary objective of a validation
study is to estimate s and S. However, the
prevalence may also be of interest, and
Figure 2. Representation of data from two-stage
designs.
could be included in the development that
follows with little trouble.
A method ofestimation can be devised
for designs A and B by treating the r indi-
viduals not included in the second stage
sample as having missing data for the gold
standard PDAN. In design A, the m indi-
viduals included in the second stage are
selected randomly without regard to their
SDAN status. Conversely, the rindividuals
not included in the second stage can also
be considered a simple random sample of
the Nindividuals in the first stage.
For the second stage of design B, mo
individuals are selected randomly from
among the No SDAN negative individuals
identified in the first stage, and ml individ-
uals are selected randomly from the N1
SDAN positive individuals. Thus the prob-
ability ofhaving a missing value of PDAN
(i.e., not being included in the second
stage) depends upon SDAN status.
For both design A and design B, the
data for PDAN are what Little and Rubin
(6) refer to as "missing at random." In
fact, they discuss a closely related problem
in their chapter on models for partially
classified contingency tables. In the section
dealing with monotone missing data pat-
terns, they give formulas for the maximum
likelihood estimates of the elements of 0,
which in this case is the joint distribution
ofPDAN and SRAN. These formulas may
be written as
A = mii +(mii/mi)r,] [1
N
Intuitively, the estimators can be
thought of as distributing the individuals
not selected for the second stage between
the two PDAN classifications. Formulas
for the elements ofthe asymptotic covari-
ance matrix of e are given in Little and
Rubin (6, section 9.2.3). This covariance
matrix will be denoted as X6. More
detailed expressions, provided in the
appendix to the current article, clearly
illustrate the dependence ofthe precision
ofthe distribution estimates on the choice
ofN, m1, and mo.
Consistent and efficient estimates for s
and Sare easily obtained as
A A
s^ A1 A and S= 00 . [2]
7[01 + ir1 I 7roo + 7[10
Using a delta method approximation,
the asymptotic variances ofSand sare
(dq) dq)
Var(S)
=
3dq ,0d
[3]
where
and
(CS _ 1 0
-9) (Too +7loj)2-7roo
Consistent estimates ofthe variances of
sand Sare obtained by replacing Tic. by the
estimates YrC.
Efficiency Calculations
The variance formulas given in Equation 3
can be used to compare the efficiency of
designs A and B for a given sensitivity,
specificity, prevalence, and first- and sec-
ond-stage sample sizes. The coefficients of
variations CV(s) = \/Wlar7iIs and CV(S)
= s\/Var)/s are used as a basis for the
comparisons shown in this section.
Figure 3 shows the coefficients ofvaria-
tion for sensitivity and specificity for a first
stage sample size of N= 10,000, a second
stage sample size of m = 400, and a range
ofvalues for ml in design B. A sensitivity
of s = 0.9, a specificity of S= 0.7, and a
prevalence of 7t = 0.15 are assumed. For
design A, ml, the number of PDAN posi-
tives in the second stage, is not controlled,
and the coefficients ofvariation are shown
as constant over all values of mlI. The plots
reveal that, in design B, an increase in ml
tends to increase the imprecision ofestima-
tion for sensitivity and decrease the impre-
cision for specificity. This reflects the
nature ofthe adjustment for the stratified
sampling scheme.
Figure 4 shows the sum of the coeffi-
cients of variation for sensitivity and
specificity for designs A and B. All the
assumptions are the same as in Figure 3,
except that the lower panel uses a sensitiv-
ityofs= 0.99. The results show that design
B is better than design A for only a small
range ofvalues for ml for a sensitivity of
0.9, whereas a fairly broad range ofvalues
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Figure 3. Coefficients of variation (CV) for specificity
and specificity as a function of relative stratum sizes.
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Figure 4. Total coefficient of variation, for two differ-
ent sensitivities.
Table 1. Optimal sample sizes and coefficients of variation for estimates of sensitivity and specificity by design
type and test characteristics of SRAN.
Assumed test characteristics Design B stratified second-stage sample
for SRAN Optimal second-stage sample sizes Coefficient of variation
Sensitivity Specificity SRAN, + SRAN, - Sensitivity, CV% Specificity, CV %
0.7 0.7 129 271 7.9 2.3
0.7 0.9 87 313 7.8 1.3
0.9 0.7 126 274 4.0 2.4
0.9 0.9 97 303 4.2 1.4
for m1 gives an improved precision for s=
0.99.
A Validation Study for SRAN
The ability to self-diagnose atypical nevi
has important implications for screening
efforts aimed at prevention and early detec-
tion of melanoma. If it can be shown that
atypical nevi are accurately self-reported,
large population surveys aimed at targeting
high risk groups for intervention or preven-
tion, could be inexpensively conducted
through mail surveys. In addition to
screening applications, the validation study
may provide a foundation for population-
based follow-up studies of melanoma risk
associated with atypical nevi, case-control
evaluation of risk factors for atypical nevi,
and preventive efforts against melanoma.
In the recent survey in Sweden, 50,000
women between the ages of 35 and 55
(above) were asked to examine their lower
extremities for the presence of irregular
moles resembling the atypical nevi pictured
in color photographs. A proposed valida-
tion study would evaluate self-screening
efforts of survey respondents living in the
Uppsala area using the two-stage design
proposed in this article (L. Titus-Ernstoff,
unpublished grant application).
In the first stage, a random sample of
2000 women living in one of two counties
adjacent to the Uppsala medical facilities
will be selected from among the respon-
dents to the original survey. Based upon
the results of a population-based study of
atypical nevi in Gothenburg, Sweden (2,3),
it is estimated that about 300 of the 2000
women who live in the eligible counties
will report an atypical nevus. A total of400
women will be selected randomly for the
second-stage validation study. Study
recruits will undergo a physician-con-
ducted skin examination, during which
pigmentation characteristics-including
mole counts-and atypical mole counts
will be recorded.
Table 1 shows optimal strata sizes and
coefficients ofvariation for design B, as
applied to the Gothenburg example. Four
assumptions are used for sensitivity and
specificity. Anticipated coefficients ofvaria-
tion are shown for s and S. These results
demonstrate that a two-stage design for
measuring sensitivity and specificity can
improve on overall precision by controlling
the number of test positives and negatives
in the second stage.
Discussion
A new proposal for two-stage designs of
validation studies has been presented.
These designs may lower the cost ofvalida-
tion studies by reducing the use of the
more expensive gold standard measurement.
A method of estimation has been derived
by using methods for missing data.
It should be noted that similar issues
have been been considered in investigations
of "verification" or "work-up bias" (7) in
diagnostic test assessment. An example of
such a situation might be a study of
"silent" coronary heart disease in which
determining the gold standard disease
classification would involve giving an inva-
sive test to populations of apparently
healthy individuals, thus incurring a high
degree of noncompliance. In these situa-
tions, the decision to apply the invasive
procedure may be influenced by the results
of the screening test, with a positively
screened individual being more likely to
receive the gold standard. This selection
can bias the estimate ofthe operating char-
acteristics ofthe tests, and has been termed
work-up bias.
The two-stage design suggested in this
paper can be viewed as a studywhich delib-
erately incurs work-up bias. The estimates
of sensitivity and specificity presented
using corrections for missing data are
equivalent to the bias-corrected estimators
suggested by Begg and Greenes (7).
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Appendix
LareSample CovarianceMatrixfor 6
Little and Rubin (6, section 9.2.3) give estimates ofthe large sam-
ple covariance matrix of ', So, as follows. The diagonal elements
are given by
Va rij) m 1-_ -+C _^ | [4]
A A
C0 LIV( 7rij n 7rij )=
where IC t -itf/ (7 o +fitl) and c = m (ft io +*iil)/mi- 1. The off-
diagona['e'lemejnt+s are given as
A A
Cov(k11,7kj ) ,A(i A i') [
m
To obtain asymptotic variances for the purposes of comparing
designs, the estimates in these formulas are replaced by the value of
the parameters 6. To compute the asymptotic variances for design
A, cCis set to 0.
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